Healthcare
Cryonics: Putting Death on Ice
Cryonics: Putting Death on Ice
There is a potent thread winding its way through generations of human culture. From Ancient Egyptian rituals to Kurzweil’s Singularity, many paths have sprung up leading to the same elusive destination: immortality.
Today, the concept is as popular as it’s ever been, and technological advances are giving people hope that immortality, or at very least radical life extension, may be within reach. Is modern technology advanced enough to give people a second chance through cryonics?
Today’s infographic, courtesy of Futurism, tackles our growing fascination with putting death on ice.
The Prospect of Immortality
Robert C. W. Ettinger’s seminal work, The Prospect Of Immortality, detailed many of the scientific, moral, and economic implications of cryogenically freezing humans for later reanimation. It was after that book was published in 1962 that the idea of freezing one’s body after death began to take hold.
One of the most pressing questions is, even if we’re able to revive a person who has been cryogenically preserved, will the person’s memories and personality remain intact? Ettinger posits that long-term memory is stored in the brain as a long-lasting structural modification. Basically, those memories will remain, even if the brain’s “power is turned off”.
Descending into the Deep-Freeze
There are three main steps in the cryogenic process:
1) Immediately after a patient dies, the body is cooled with ice packs and transported to the freezing location.
2) Next, blood is drained from the patient’s body and replaced with a cryoprotectant (basically the same antifreeze solution used to transport organs destined for transplant).
3) Finally, once the body arrives at the cryonic preservation facility, the body is cooled to -196ºC (-320.8ºF) over the course of two weeks. Bodies are generally stored upside-down in a tank of liquid nitrogen.
The Economics of Cryopreservation
At prices ranging from about $30,000 to $200,000, cryopreservation may sound like an option reserved for the wealthy, but many people fund the procedure by naming a cryonics company as the primary benefactor of their life insurance policy. Meanwhile, in the event of a death that doesn’t allow for preservation of the body, the money goes to secondary beneficiaries.
Even if we do eventually find a way to reanimate frozen humans, another important consideration is how those people would take care of themselves financially. That’s where a cryonics or personal revival trust comes into play. A twist on a traditional dynastic trust, this arrangement ensures that there are funds to cover costs of the cryopreservation, as well as ensure the grantor would have assets when they’re unthawed. Of course, there are risks involved beyond the slim possibility of reanimation. The legal code in hundreds of years could be vastly different than today.
If you created a trust for specific purposes in 1711, it is unlikely it would function in the same way today.
– Kris Knaplund, Law Professor, Pepperdine University
Cold Humans, Hot Market
At last count, there are already 346 people in the deep freeze, with thousands more on the waiting list. As technology improves, those numbers are sure to continue rising.
Time will tell whether cryonically preserved people are able to cheat death. In the meantime? The cryonics industry is alive and well.
Healthcare
Innovation in Virology: Vaccines and Antivirals
Vaccine development has grown six-fold since 1995. Learn how virology, the study of viruses, is driving innovation in the healthcare industry.

Innovation in Virology: Vaccines and Antivirals
The COVID-19 pandemic affected millions of people worldwide and brought renewed focus to virology—the study of viruses.
However, impact made by viruses extends far beyond the SARS-CoV-2 virus that causes COVID-19. There are 24 viruses that have each infected more than 80 million people globally, from hepatitis to influenza.
In this graphic from MSCI, we uncover innovation in vaccines and antivirals and the related market opportunities.
What is a Virus?
A virus is a microscopic infectious agent that replicates within living cells. It may cause disease in its host. New viruses can emerge at any time as a result of mutation, or when viruses transfer from animals to humans.
Through virology, scientists are continuously finding new ways to fight against infectious diseases. Two main types of anti-infectives are available: vaccines and antivirals.
Rapid Innovation in Vaccines
Vaccines are substances designed to prevent people from getting infected with a disease or experiencing serious symptoms.
The number of vaccines has increased dramatically over the last three decades. From 2020 to 2021 alone, the number of approved vaccines or clinical candidates jumped by 13%.
Year | Vaccines Approved or in Development |
---|---|
1995 | 240 |
1996 | 262 |
1997 | 309 |
1998 | 323 |
1999 | 374 |
2000 | 415 |
2001 | 462 |
2002 | 472 |
2003 | 509 |
2004 | 531 |
2005 | 564 |
2006 | 610 |
2007 | 606 |
2008 | 704 |
2009 | 751 |
2010 | 866 |
2011 | 893 |
2012 | 880 |
2013 | 943 |
2014 | 1075 |
2015 | 1179 |
2016 | 1374 |
2017 | 1397 |
2018 | 1340 |
2019 | 1356 |
2020 | 1388 |
2021 | 1567 |
Data is a snapshot in time and reflects all vaccines ever approved (and not taken off the market) plus all vaccines in development as of the noted year (for which a trial has not been canceled).
Not only that, it’s possible to have shorter approval timelines. COVID-19 vaccines were approved within 11 months, much more quickly than the 2000-2020 average of 10 years.
In the time between an outbreak and vaccine development, antivirals can play a vital role.
Antivirals: The Second Line of Defense in Virology
Antivirals are drugs that slow or prevent the growth of a virus and treat disease symptoms. They are especially important tools for diseases that do not have an associated vaccine.
In 2021, there were nearly six times as many approved antivirals as there were in 1995. Not only that, antiviral uses have grown to include the potential prevention and treatment of HIV, COVID-19, and a number of other diseases.
Year | Approved Antivirals in the U.S. | Reasons for Using Antivirals |
---|---|---|
1995 | 10 | 12 |
1996 | 10 | 12 |
1997 | 12 | 12 |
1998 | 13 | 13 |
1999 | 16 | 13 |
2000 | 18 | 13 |
2001 | 19 | 13 |
2002 | 20 | 13 |
2003 | 21 | 13 |
2004 | 21 | 13 |
2005 | 22 | 13 |
2006 | 23 | 13 |
2007 | 24 | 13 |
2008 | 26 | 13 |
2009 | 27 | 14 |
2010 | 27 | 14 |
2011 | 30 | 14 |
2012 | 30 | 15 |
2013 | 34 | 15 |
2014 | 37 | 15 |
2015 | 41 | 16 |
2016 | 44 | 16 |
2017 | 47 | 16 |
2018 | 49 | 17 |
2019 | 49 | 17 |
2020 | 53 | 19 |
2021 | 57 | 20 |
The potential prevention (prophylaxis) and treatment of the same virus are counted as separate uses. Data is cumulative and reflects all antivirals ever approved (and not taken off the market) and all reasons ever approved for using antivirals (that have not been rescinded).
Innovation in virology—and the potential for future developments—is leading to a growing industry.
Expanding Market Opportunities
With opportunities growing and approval times shortening, more companies are entering the market.
Year | Companies Developing Vaccines/Antivirals |
---|---|
1995 | 66 |
1996 | 73 |
1997 | 80 |
1998 | 81 |
1999 | 87 |
2000 | 111 |
2001 | 125 |
2002 | 140 |
2003 | 154 |
2004 | 144 |
2005 | 146 |
2006 | 163 |
2007 | 167 |
2008 | 196 |
2009 | 203 |
2010 | 230 |
2011 | 237 |
2012 | 255 |
2013 | 277 |
2014 | 289 |
2015 | 310 |
2016 | 362 |
2017 | 392 |
2018 | 374 |
2019 | 370 |
2020 | 383 |
2021 | 484 |
Data is a snapshot in time and reflects all companies developing vaccines or antivirals as of the noted year. If a company stops being active in the space or ceases to exist, they are removed from the total.
As they work to develop new vaccines and antivirals, companies are conducting clinical trials for many diseases beyond COVID-19 such as respiratory infections and sepsis.
Virology is leading to a number of groundbreaking technologies and therapies, transforming healthcare along the way.

Explore the MSCI Virology Index now.

-
Personal Finance5 months ago
Ranked: The Best U.S. States for Retirement
Getting ready for retirement? See which states score the highest in terms of affordability, quality of life, and health care.
-
Cannabis6 months ago
Timeline: Cannabis Legislation in the U.S.
At the federal level, cannabis is illegal, but state laws differ. This graphic looks at the timelines of cannabis legislation in the U.S.
-
Science11 months ago
Visualizing the Composition of Blood
Despite its simple appearance, blood is made up of many microscopic elements. This infographic visualizes the composition of blood.
-
Healthcare1 year ago
Visualizing the Relationship Between Cancer and Lifespan
New research links mutation rates and lifespan. We visualize the data supporting this new framework for understanding cancer.
-
Misc1 year ago
Explainer: What to Know About Monkeypox
What is monkeypox, and what risk does it pose to the public? This infographic breaks down the symptoms, transmission, and more.
-
Healthcare2 years ago
Visualizing How COVID-19 Antiviral Pills and Vaccines Work at the Cellular Level
Despite tackling the same disease, vaccines and antiviral pills work differently to combat COVID-19. We visualize how they work in the body.
-
Maps3 weeks ago
The Incredible Historical Map That Changed Cartography
-
Markets7 days ago
The $109 Trillion Global Stock Market in One Chart
-
China4 weeks ago
Charted: Six Red Flags Pointing to China’s Economy Slowing Down
-
VC+3 weeks ago
What’s New on VC+ in September
-
Real Estate5 days ago
Ranked: 15 of the World’s Least Affordable Housing Markets
-
Markets4 weeks ago
The 25 Best Stocks by Shareholder Wealth Creation (1926-2022)
-
Business2 weeks ago
Ranked: The 20 Best Franchises to Open in the U.S.
-
Markets5 days ago
Visualizing the Most Sought-After Entry Level Jobs in 2023